Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180 million

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.

RCKT

0.00
  • Rocket Pharmaceuticals closed the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD 180 million.
  • The voucher was awarded in March 2026 tied to the FDA approval of KRESLADI for severe leukocyte adhesion deficiency-I.
  • Pro forma cash, cash equivalents, and investments rose to about USD 322.6 million from USD 144.4 million as of March 31, 2026.
  • The company expects the added liquidity to fund operations into the second quarter of 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260612407717) on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.